Paper-based lateral flow immunoassays (LFIAs) are one of the most widely used point-of-care (PoC) devices; however, their application in early disease diagnostics is often limited due to insufficient ...

The monoclonal antibody (mAb) used in a traditional Lateral Flow Immunoassay (LFIA) has many limitations, particularly related to its poor affinity, specificity, and stability. In this study, a ...

α-synuclein seed amplification assay (SAA) positivity has been proposed as a diagnostic biomarker for Parkinson's disease. However, studies of the prognostic value of this biomarker have been limited ...